-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Autolus Therapeutics, Lowers Price Target to $10

Benzinga·01/12/2026 15:35:31
Listen to the news
Needham analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and lowers the price target from $11 to $10.